# Chris Hollowood

> Chris Hollowood is a Series B investor at Syncona Partners LLP backing Biotechnology. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Syncona Partners LLP](https://shizune.co/investors/profile/syncona-partners-llp)
- Location: London, United Kingdom
- Total investments: 9
- Last investment: Oct 2024
- Lead investor: 44%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chrishollowood/
- Facebook: https://www.facebook.com/cjhollowood

Chris Hollowood is a Series B investor at Syncona Partners LLP in London focused on Biotechnology and Health Care. Chris is the Chief Investment Officer of Syncona Investment Management Ltd.He is currently Chairman at five Syncona companies: NightStar Therapeutics (NASDAQ:NITE), Freeline Therapeutics, Gyroscope Therapeutics, Swan Therapeutics and Orbit Biomedical. He has been instrumental in their foundation and development including the acquisition of a genetherapy manufacturing platform from Rentschler Biotechnologie on behalf of Freeline.Previously, he was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 44% |
| Health Care | 3 | 33% |
| Medical | 2 | 22% |
| Therapeutics | 2 | 22% |
| Genetics | 1 | 11% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 33% |
| Series A | 2 | 22% |
| Series C | 2 | 22% |
| Funding Round | 1 | 11% |
| Venture - Series Unknown | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 44% |
| United States | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Purespring Therapeutics | Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally. | $104.5M | Series B | Oct 09, 2024 |  |
| Spur Therapeutics | Spur Therapeutics is a clinical-stage biotechnology business dedicated to creating life-changing medicines for crippling chronic illnesses. | $50M |  | Jun 17, 2024 |  |
| Beacon Therapeutics | Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $170M | Series B | Jun 03, 2024 |  |
| SwanBio Therapeutics | SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders. | $10M | Venture - Series Unknown | Oct 04, 2023 |  |
| Beacon Therapeutics | Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $120.1M | Series A | Jun 12, 2023 |  |
| SwanBio Therapeutics | SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders. | $56M | Series B | May 18, 2022 |  |
| Gyroscope Therapeutics | Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatmentdelivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON.Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016. | $148.6M | Series C | Mar 26, 2021 |  |
| SwanBio Therapeutics | SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders. | $52M | Series A | Apr 23, 2020 |  |
| Beacon Therapeutics | Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $75M | Series C |  |  |

9 of 9 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 7 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation) — VC Fund, 3 deals together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 2 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-science-enterprises) — VC Fund, 2 deals together
- [British Patient Capital](https://shizune.co/investors/profile/british-patient-capital) — VC Fund, 1 deal together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 1 deal together

## About Syncona Partners LLP

VC Fund · London, United Kingdom

Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Their vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.They seek to partner with the best, brightest and most ambitious minds in scienceto build globally competitive businesses. They take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. They focus on delivering dramatic efficacy for patients in areas of high unmet need.Syncona is aligned with two of the premium charitable funders in UK science, The Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in their business. They make a donation of 0.3% of Net Asset Value to a range of charities each year.

5 contacts available at Syncona Partners LLP.

| Name | Title | Profile |
| --- | --- | --- |
| Edward Hodgkin | Partner | https://shizune.co/investors/profile/edward-hodgkin |
| Magdalena Jonikas | Partner | https://shizune.co/investors/profile/magdalena-jonikas-90a8 |
| Chris Hollowood | Chief Investment Officer | https://shizune.co/investors/profile/chris-hollowood |
| Chris Hollowood | Chief Investment Officer | https://shizune.co/investors/profile/christopher-hollowood |
| Christian Groendahl | Partner | https://shizune.co/investors/profile/christian-groendahl |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Chris Hollowood invest in?

Chris Hollowood invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris Hollowood last invest?

The most recent investment recorded for Chris Hollowood closed in Oct 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co